TY - JOUR
T1 - Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals
T2 - Diversification of Circulating Lineages and Antimicrobial Resistance
AU - Iovleva, Alina
AU - Mustapha, Mustapha M.
AU - Griffith, Marissa P.
AU - Komarow, Lauren
AU - Luterbach, Courtney
AU - Evans, Daniel R.
AU - Cober, Eric
AU - Richter, Sandra S.
AU - Rydell, Kirsten
AU - Arias, Cesar A.
AU - Jacob, Jesse T.
AU - Salata, Robert A.
AU - Satlin, Michael J.
AU - Wong, Darren
AU - Bonomo, Robert A.
AU - Van Duin, David
AU - Cooper, Vaughn S.
AU - Van Tyne, Daria
AU - Doi, Yohei
N1 - Funding Information:
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R21AI135522 and in part under award number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.I. was supported through the Physician Scientist Incubator Program at the University of Pittsburgh sponsored by the Burrows Wellcome Fund. R.A.B. was supported by the National Institutes of Health under award number R01AI072219. V.S.C. was supported by a research grant from the National Institutes of Health (U01AI124302) and, in part, by PA CURES grant 4100085725 with the Pennsylvania Department of Health. D.V.T. was supported by a research grant from the National Institutes of Health (R00EY02822). Y.D. was supported by research grants from the National Institutes of Health (R01AI104895, R21AI151362). S.S.R. reports prior employment by bioM?rieux (August 2019 to May 2021) and research funding from BD Diagnostics, Hologic, DiaSorin, and Lifescale while employed in the department of Laboratory Medicine at Cleveland Clinic. C.L. was supported by a research grant from the National Institutes of Health, T32GM086330. C.A.A. was supported by NIH/NIAID grants R01-AI148342-01, R01AI134637, K24-AI121296, and P01-AI152999-01.
Funding Information:
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R21AI135522 and in part under award number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. A.I. was supported through the Physician Scientist Incubator Program at the University of Pittsburgh sponsored by the Burrows Wellcome Fund. R.A.B. was supported by the National Institutes of Health under award number R01AI072219. V.S.C. was supported by a research grant from the National Institutes of Health (U01AI124302) and, in part, by PA CURES grant 4100085725 with the Pennsylvania Department of Health. D.V.T. was supported by a research grant from the National Institutes of Health (R00EY02822). Y.D. was supported by research grants from the National Institutes of Health (R01AI104895, R21AI151362). S.S.R. reports prior employment by bioMérieux (August 2019 to May 2021) and research funding from BD Diagnostics, Hologic, DiaSorin, and Lifescale while employed in the department of Laboratory Medicine at Cleveland Clinic. C.L. was supported by a research grant from the National Institutes of Health, T32GM086330. C.A.A. was supported by NIH/NIAID grants R01-AI148342-01, R01AI134637, K24-AI121296, and P01-AI152999-01.
Publisher Copyright:
Copyright © 2022 Iovleva et al.
PY - 2022/4/26
Y1 - 2022/4/26
N2 - Carbapenem-resistant Acinetobacter baumannii (CR
Ab) is a major cause of health care-associated infections. CR
Ab is typically multidrug resistant, and infection is difficult to treat. Despite the urgent threat that CR
Ab poses, few systematic studies of CR
Ab clinical and molecular epidemiology have been conducted. The Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP) is designed to investigate the clinical characteristics and contemporary population structure of CR
Ab circulating in U.S. hospital systems using whole-genome sequencing (WGS). Analysis of the initial 120 SNAP patients from four U.S. centers revealed that CR
Ab remains a significant threat to hospitalized patients, affecting the most vulnerable patients and resulting in 24% all-cause 30-day mortality. The majority of currently circulating isolates belonged to ST2
Pas, a part of clonal complex 2 (CC2), which is the dominant drug-resistant lineage in the United States and Europe. We identified three distinct sublineages within CC2, which differed in their antibiotic resistance phenotypes and geographic distribution. Most concerning, colistin resistance (38%) and cefiderocol resistance (10%) were common within CC2 sublineage C (CC2C), where the majority of isolates belonged to ST2
Pas/ST281
Ox. Additionally, we identified ST499
Pas as the most common non-CC2 lineage in our study. Our findings suggest a shift within the CR
Ab population in the United States during the past 10 years and emphasize the importance of real-time surveillance and molecular epidemiology in studying CR
Ab dissemination and clinical impact.
IMPORTANCE Carbapenem-resistant Acinetobacter baumannii (CR
Ab) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CR
Ab in the United States, clinical CR
Ab isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping. Key findings included emergence of new sublineages within the globally predominant clonal complex 2 (CC2), increased colistin and cefiderocol resistance within one of the CC2 sublineages, and emergence of ST499
Pas as the dominant non-CC2 CR
Ab lineage in U.S. hospitals.
AB - Carbapenem-resistant Acinetobacter baumannii (CR
Ab) is a major cause of health care-associated infections. CR
Ab is typically multidrug resistant, and infection is difficult to treat. Despite the urgent threat that CR
Ab poses, few systematic studies of CR
Ab clinical and molecular epidemiology have been conducted. The Study Network of Acinetobacter as a Carbapenem-Resistant Pathogen (SNAP) is designed to investigate the clinical characteristics and contemporary population structure of CR
Ab circulating in U.S. hospital systems using whole-genome sequencing (WGS). Analysis of the initial 120 SNAP patients from four U.S. centers revealed that CR
Ab remains a significant threat to hospitalized patients, affecting the most vulnerable patients and resulting in 24% all-cause 30-day mortality. The majority of currently circulating isolates belonged to ST2
Pas, a part of clonal complex 2 (CC2), which is the dominant drug-resistant lineage in the United States and Europe. We identified three distinct sublineages within CC2, which differed in their antibiotic resistance phenotypes and geographic distribution. Most concerning, colistin resistance (38%) and cefiderocol resistance (10%) were common within CC2 sublineage C (CC2C), where the majority of isolates belonged to ST2
Pas/ST281
Ox. Additionally, we identified ST499
Pas as the most common non-CC2 lineage in our study. Our findings suggest a shift within the CR
Ab population in the United States during the past 10 years and emphasize the importance of real-time surveillance and molecular epidemiology in studying CR
Ab dissemination and clinical impact.
IMPORTANCE Carbapenem-resistant Acinetobacter baumannii (CR
Ab) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CR
Ab in the United States, clinical CR
Ab isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping. Key findings included emergence of new sublineages within the globally predominant clonal complex 2 (CC2), increased colistin and cefiderocol resistance within one of the CC2 sublineages, and emergence of ST499
Pas as the dominant non-CC2 CR
Ab lineage in U.S. hospitals.
KW - Acinetobacter baumannii
KW - carbapenem resistance
KW - clinical epidemiology
KW - molecular epidemiology
KW - Interleukin-1 Receptor-Like 1 Protein
KW - Carbapenems/pharmacology
KW - Colistin
KW - Humans
KW - Drug Resistance, Bacterial
KW - Anti-Bacterial Agents/pharmacology
KW - Microbial Sensitivity Tests
KW - United States/epidemiology
KW - Hospitals
KW - beta-Lactamases/genetics
KW - Acinetobacter Infections/microbiology
UR - http://www.scopus.com/inward/record.url?scp=85129027788&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129027788&partnerID=8YFLogxK
U2 - 10.1128/mbio.02759-21
DO - 10.1128/mbio.02759-21
M3 - Article
C2 - 35311529
AN - SCOPUS:85129027788
SN - 2161-2129
VL - 13
SP - e0275921
JO - mBio
JF - mBio
IS - 2
ER -